Xencor Stock Hits Day Low of $11.17 Amid Price Pressure

Xencor, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, experienced a significant decline today, with its stock price dropping by 10.96%. The stock reached an intraday low of USD 11.17, reflecting ongoing challenges in its market performance.
Over the past year, Xencor has faced considerable headwinds, with a total return of -40.89%, significantly underperforming the S&P 500, which gained 14.44% during the same period. Year-to-date, the stock has seen a decline of 45.91%, further highlighting its struggles compared to the broader market, which has risen by 13.14%.

Despite a recent uptick in net sales, which grew by 37.1% to USD 43.61 million in March 2025, the company continues to report negative profitability metrics, including a pre-tax profit of -34.18 million. The return on equity remains low at 0.66%, indicating challenges in generating shareholder value. Additionally, Xencor's high institutional holdings at 100% suggest that larger investors are closely monitoring its performance amid these fluctuations.